78 related articles for article (PubMed ID: 29104242)
1. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer.
Chen Y; Meng L; Wang W; Ye L; Huang L; Wang C; Wang S; Li M; Pei Y; Zhang S; Zou Y; Xu Y
Eur J Med Chem; 2023 Dec; 261():115846. PubMed ID: 37862816
[TBL] [Abstract][Full Text] [Related]
2. Crafting mono- and novel bis-methylated pyrroloquinoxaline derivatives from a shared precursor and its application in the total synthesis of marinoquinoline A.
Damai M; Guzzardi N; Lewis V; Rao ZX; Sykes D; Patel B
RSC Adv; 2023 Oct; 13(42):29561-29567. PubMed ID: 37822662
[TBL] [Abstract][Full Text] [Related]
3. Amidine- and Amidoxime-Substituted Heterocycles: Synthesis, Antiproliferative Evaluations and DNA Binding.
Maračić S; Grbčić P; Shammugam S; Radić Stojković M; Pavelić K; Sedić M; Kraljević Pavelić S; Raić-Malić S
Molecules; 2021 Nov; 26(22):. PubMed ID: 34834151
[TBL] [Abstract][Full Text] [Related]
4. Purine and Purine Isostere Derivatives of Ferrocene: An Evaluation of ADME, Antitumor and Electrochemical Properties.
Rep V; Piškor M; Šimek H; Mišetić P; Grbčić P; Padovan J; Gabelica Marković V; Jadreško D; Pavelić K; Kraljević Pavelić S; Raić-Malić S
Molecules; 2020 Mar; 25(7):. PubMed ID: 32235404
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Novel Benzenesulfonamide Analogue That Inhibits Proliferation and Metastasis Against Ovarian Cancer OVCAR-8 Cells.
Jia Y; Li M; Cao Y; Feng W; Li X; Xue W; Shi H
Drug Des Devel Ther; 2020; 14():207-216. PubMed ID: 32021105
[TBL] [Abstract][Full Text] [Related]
6. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines.
Núñez MC; Díaz-Gavilán M; Conejo-García A; Cruz-López O; Gallo MA; Espinosa A; Campos JM
Curr Med Chem; 2008; 15(25):2614-31. PubMed ID: 18855682
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases.
Bistrović A; Harej A; Grbčić P; Sedić M; Kraljević Pavelić S; Cetina M; Raić-Malić S
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29104242
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors.
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2018 May; 151():836-848. PubMed ID: 29684894
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
11. Novel Bis- and Mono-Pyrrolo[2,3-
Bistrović Popov A; Vianelo R; Grbčić P; Sedić M; Pavelić SK; Pavelić K; Raić-Malić S
Molecules; 2021 Jun; 26(11):. PubMed ID: 34206076
[TBL] [Abstract][Full Text] [Related]
12. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
14. Recent advances (2015-2016) in anticancer hybrids.
Kerru N; Singh P; Koorbanally N; Raj R; Kumar V
Eur J Med Chem; 2017 Dec; 142():179-212. PubMed ID: 28760313
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
